Eckert & Ziegler SE (STU:EUZ) EBIT: €78.3 Mil (TTM As of Mar. 2026)


STU:EUZ Eckert & Ziegler SE STU:EUZ
98 GF Score
Price €15.22
GF Value €16.05
Valuation Fairly Valued
View Full Analysis

What is Eckert & Ziegler SE EBIT?

Eckert & Ziegler SE STU:EUZ -0.91% 98 EBIT is €78.3 Mil as of Mar. 2026. GuruFocus rates STU:EUZ with a GF Score™ of 98/100 and a GF Value™ of €16.05 (Fairly Valued).

Eckert & Ziegler SE's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €16.7 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €78.3 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Eckert & Ziegler SE's annualized ROC % for the quarter that ended in Mar. 2026 was 13.26%. Eckert & Ziegler SE's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 36.01%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Eckert & Ziegler SE's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 8.84%.


Eckert & Ziegler SE  (STU:EUZ) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Eckert & Ziegler SE's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=63.892 * ( 1 - 33.24% )/( (311.861 + 331.394)/ 2 )
=42.6542992/321.6275
=13.26 %

where

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=476.529 - 21.264 - ( 123.871 - max(0, 74.86 - 255.445+123.871))
=331.394

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Eckert & Ziegler SE's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=66.716/( ( (135.532 + max(40.997, 0)) + (140.153 + max(53.867, 0)) )/ 2 )
=66.716/( ( 176.529 + 194.02 )/ 2 )
=66.716/185.2745
=36.01 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(44.958 + 45.972 + 12.268) - (17.305 + 0 + 44.896)
=40.997

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(51.644 + 47.774 + 19.625) - (21.264 + 0 + 43.912)
=53.867

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Eckert & Ziegler SE's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=78.264/884.958
=8.84 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eckert & Ziegler SE EBIT Related Terms


Eckert & Ziegler SE EBIT Historical Data

* Premium members only.

The historical data trend for Eckert & Ziegler SE's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eckert & Ziegler SE EBIT Chart

Eckert & Ziegler SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 47.58 47.04 46.30 62.11 77.25

Eckert & Ziegler SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.66 18.83 15.14 27.62 16.68

STU:EUZ vs ABT, SYK, MDT: EBIT Comparison

For the Medical Devices subindustry, Eckert & Ziegler SE's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eckert & Ziegler SE EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Eckert & Ziegler SE's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Eckert & Ziegler SE's EV-to-EBIT falls into.


STU:EUZ
98GF Score
Eckert & Ziegler SE STU:EUZ
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eckert & Ziegler SE EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €78.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €78.3 Mil mean?
Eckert & Ziegler SE (STU:EUZ) has a EBIT of €78.3 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Eckert & Ziegler SE.
Is Eckert & Ziegler SE's EBIT too high?
Eckert & Ziegler SE's current EBIT is €78.3 Mil. Overall, Eckert & Ziegler SE has a GF Score™ of 98/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eckert & Ziegler SE's EBIT compare to ABT and SYK?
Eckert & Ziegler SE's EBIT of €78.3 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Eckert & Ziegler SE. Eckert & Ziegler SE's current EBIT is €78.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eckert & Ziegler SE stock overvalued right now?
Based on GuruFocus' analysis, Eckert & Ziegler SE (STU:EUZ) is currently considered Fairly Valued. The stock's GF Value™ is €16.05, compared to a current price of €15.22 — trading 5.2% below its estimated fair value. The current EBIT is €78.3 Mil. Eckert & Ziegler SE's overall GF Score™ is 98/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Eckert & Ziegler SE (STU:EUZ), the current EBIT is €78.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eckert & Ziegler SE (STU:EUZ) Overvalued in 2026?

Based on GuruFocus' analysis, Eckert & Ziegler SE stock appears to be undervalued. The current stock price of €15.22 is trading 5.2% below its estimated GF Value™ of €16.05. GuruFocus considers Eckert & Ziegler SE to be Fairly Valued.

Key valuation signals for STU:EUZ:

  • EBIT: €78.3 Mil
  • GF Value™: €16.05 vs. price of €15.22 (5.2% below fair value)
  • GF Score™: 98/100

No single metric tells the full story. See the STU:EUZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eckert & Ziegler SE Business Description

Address Robert-Rossle-Street 10, Berlin, BB, DEU, 13125
Eckert & Ziegler SE is a holding company with specialised in the processing of radioisotopes and the development, production and sale of isotope technology components, radiopharmaceuticals and related products. It is an international manufacturer of isotope technology components for medical, scientific, and industrial applications. The group's products are mainly used in cancer therapy, nuclear imaging, and industrial metrology. The company's segments are Medical, Isotope Products, and Other. The majority of revenue comes from Medical segment which provides pharmaceutical-quality radioactive ingredients and markets products for the treatment and diagnosis of cancers. Geographically, the company generates a majority of its revenue from Europe and then North America, Asia/Pacific, and other.
98GF Score

Get the complete analysis for STU:EUZ

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€15.22
Price
€16.05
GF Value